GlassScriptPhysician profile
Hassan M Ebrahim
NPI 1306938774
$15,634.40
in general payments reported to CMS, 2019-2025
51 companies · $3,038 in 2025
The $3,038 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,314 · 2021: $13.29 · 2022: $262 · 2023: $909 · 2024: $3,098 · 2025: $3,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,476 · Education: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,475.61 |
| Education | $570.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,197.63 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $4,191.48 | 2019-2025 | Erleada, Rybrevant, Balversa |
| Foundation Medicine, INC. | $961.14 | 2019 | |
| Pfizer INC. | $573.43 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $559.99 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $509.68 | 2021-2025 | |
| Celgene Corporation | $417.80 | 2023-2025 | Reblozyl, Pomalyst, Pomalyst |
| Incyte Corporation | $412.03 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $341.99 | 2024-2025 | Xtandi |
| Daiichi Sankyo INC. | $308.12 | 2022-2025 | Enhertu, Vanflyta, Injectafer |
| Genzyme Corporation | $258.15 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.66 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $198.21 | 2024-2025 | |
| Lilly USA, LLC | $180.53 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $162.94 | 2023-2025 | Venclexta, Polivy, Perjeta |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $148.60 | 2024-2025 | Fruzaqla |
| Glaxosmithkline, LLC. | $117.07 | 2024-2025 | Ojjaara, Blenrep |
| Array Biopharma INC | $109.34 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Stemline Therapeutics INC. | $109.13 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $107.18 | 2023-2025 | |
| Abbvie INC. | $101.80 | 2022-2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Pharmaessentia USA Corporation | $86.44 | 2024-2025 | Besremi |
| Beone Medicines USA, INC. | $83.11 | 2025 | Tevimbra, Brukinsa |
| Myriad Genetic Laboratories, INC. | $82.80 | 2023-2024 | Myrisk |
| Gilead Sciences, INC. | $77.93 | 2025 | Trodelvy |
| Sobi, INC | $75.92 | 2023-2024 | |
| Kyowa Kirin, INC. | $70.32 | 2022-2025 | Poteligeo |
| Pharmacosmos Therapeutics INC. | $69.74 | 2024-2025 | Monoferric |
| Fennec Pharmaceuticals, INC. | $61.45 | 2024-2025 | Pedmark, Fyarro |
| E.R. Squibb & Sons, L.L.C. | $58.13 | 2023-2024 | Opdivo, Eliquis |
| Regeneron Healthcare Solutions, INC. | $56.91 | 2025 | Libtayo |
| Beigene USA, INC. | $53.12 | 2025 | Brukinsa, Tevimbra |
| Geron Corporation | $49.21 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $48.04 | 2025 | Enjaymo |
| Agios Pharmaceuticals, INC. | $47.52 | 2023-2025 | Pyrukynd |
| Taiho Oncology, INC. | $45.15 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $44.58 | 2025 | Provenge |
| Sumitomo Pharma America, INC. | $44.16 | 2024-2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $27.93 | 2025 | Romvimza, Qinlock |
| Caris Mpi, INC. | $26.52 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $25.24 | 2023 | Yescarta |
| Springworks Therapeutics, INC. | $24.85 | 2025 | Ogsiveo |
| Eisai INC. | $24.62 | 2023 | |
| Azurity Pharmaceuticals, INC. | $24.50 | 2024 | Vivimusta |
| Global Blood Therapeutics, INC. | $22.82 | 2022 | |
| Mirati Therapeutics, INC. | $19.82 | 2023 | Krazati |
| Alnylam Pharmaceuticals INC. | $19.45 | 2023 | Givlaari |
| Blueprint Medicines Corporation | $17.46 | 2024 | Ayvakit |
| Blue Earth Diagnostics | $16.68 | 2024 | |
| Amgen INC. | $13.09 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Ebrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.